Sodium-glucose Co-transporter 2 Inhibitors: A Novel Molecule for Health Care Practitioners in Diabetology, Cardiology and Nephrology

Prevention and timely management of cardiovascular (CV) complications like myocardial infarction, heart failure (HF), stroke and renal complications, like chronic kidney disease (CKD) and end-stage renal disease, are important to improve the quality of life and survival in people with type 2 diabetes mellitus (T2DM). The multifaceted action of sodium-glucose co-transporter 2 inhibitors (SGLT2i) results in effective glycemic control with benefits on CV and renal risk factors, like body weight, blood pressure, uric acid and albuminuria. Robust CV and renal event reduction is reflected in the outcomes of large CV outcome trials, meta-analyses and real-world studies. Recent evidence has proven cardiac and renal benefits with SGLT2i in subjects with HF and CKD irrespective of their T2DM status. Until recently, SGLT2i was used as a glucose-lowering molecule with pleiotropic benefits, mainly by primary care practitioners and diabetologists. The potential for cardiac and renal protection in people with and without T2DM has shifted an interest in cardiologists and nephrologists to view it as a cardiac and renal molecule, respectively. Thus, the role of SGLT2i in the management of T2DM is undergoing a paradigm shift—straddling the interfaces of diabetology, cardiology, nephrology and primary care—moving away from being considered a pure antidiabetic molecule. We conducted a literature review of SGLT2i in management of T2DM along with their protective effects on CV and renal parameters in patients with or without baseline comorbidities.

Ambulatory glucose profile as an educational tool in the management of patients with type 2 diabetes mellitus

A 60-year-old male patient with Type 2 Diabetes Mellitus (T2DM) since the last two years was presented in the clinic with repeated falls. He was on dietary treatment and was also taking metformin 500 mg twice daily, on and off. His Fasting Plasma Glucose (FPG) was 116 mg/dL, Postprandial Glucose (PPG) was 140 mg/dL and Glycosylated Haemoglobin (HbA1c) was 6.4%. The complete glycaemic profile obtained from the first Ambulatory Glucose Profile (AGP) revealed that the patient was not having hypoglycaemia and has very minimal glucose fluctuations without any post-prandial excursions. The visual cue obtained from Continuous Glucose Monitoring (CGM) / AGP enabled physicians to better inform the patient on the effects of medication and lifestyle on diabetes, thereby allowing the patient to make informed treatment and lifestyle modifications. This case study sheds light on the need to recommend AGP in such cases to provide insights on the glucose trends, thereby improve patient’s confidence in the therapy, with lifestyle modification.